"It's important to note that ASCO's new guidelines only include markers with a proven clinical decision-making impact that are based on a high level of clinical validation," said Gabriel N. Hortobagyi MD, FACP, Professor and Chairman, Department of Breast Medical Oncology, The University of Texas M.D. Anderson Cancer Center. "While exciting research and multiple prognostic tools are available today, Oncotype DX is the only genomic test that has sufficient clinical evidence to support its use in clinical practice."
About Oncotype DX
Oncotype DX is the first diagnostic multi-gene expression test commercially available that has clinical evidence validating its ability to predict the likelihood of breast cancer recurrence, the likelihood of breast cancer survival and the likelihood of chemotherapy benefit. Oncotype DX has been extensively evaluated in multiple independent studies involving more than 2,600 breast cancer patients, including a large validation study published in The New England Journal of Medicine and a chemotherapy benefit study published in the Journal of Clinical Oncology. To date, over 6,000 physicians have ordered a cumulative total of more than 33,000 tests and approximately 125 million lives are now covered by reimbursement contracts and agreements. For more information about Oncotype DX, please visit http://www.oncotypedx.com.
About Genomic Health
Genomic Health, Inc. (Nasdaq: GHDX) is a life science company focused
on the development and commercialization of genomic-based clinical
laboratory services for
'/>"/>
| SOURCE Genomic Health, Inc. Copyright©2007 PR Newswire. All rights reserved |